Ellipse Technology Hires Chief Sales Officer and CFO

Ellipse Technologies Inc. recently filled two key executive positions.

Ellipse Technologies is a privately held medical technology company located in Aliso Viejo, Calif. The company is focused on orthopedic surgery by developing a new generation of magnetically adjustable implant systems based on the MAGnetic External Control, technology platform. The company’s implants are adjustable at the time of implantation and non-invasively over the course of treatment to accommodate the changing clinical needs of patients as they heal, grow or age.

Jeff Rydin joins Ellipse as chief sales officer after most recently serving as president of global sales at spine company NuVasive Inc. Prior to NuVasive, Rydin was area vice president at DePuy Spine, where he managed a $100 million division and established a sales team in the Southeastern United States during his three-year tenure. Rydin also served in various executive and leadership sales roles at Orquest (acquired by Johnson & Johnson), Symphonix, General Surgical Innovations (acquired by Tyco International), Baxter Healthcare and Xerox.

Bob Krist is Ellipse’s new chief financial officer (CFO). He most recently served as CFO at Endologix Inc., a developer of minimally invasive treatments for aortic disorders. At Endologix, Krist was responsible for building the company’s financial infrastructure, overseeing several equity capital raises. Prior to Endologix, he served as CEO of CardioNet Inc., a privately held marketer of mobile cardiac outpatient telemetry tools and services, where he also played a key role in developing the company’s business model and overseeing several equity and debt capital raises. Krist has held several other executive management positions at public and private healthcare companies.

Ed Roschak, president and CEO of Ellipse commented: “The addition of these two seasoned executives significantly enhances our leadership team. As NuVasive’s president of global sales, Jeff helped grow revenues from $38 million to over $600 million. Bob offers deep public company CFO and SEC reporting experience. While at Endologix, the company experienced rapid product adoption while he oversaw several public equity financings. We are very fortunate to have these two highly experienced, proven executives join the Ellipse team, and we look forward to the contributions they will both make as we drive adoption of our adjustable implant technology.”